Hopefully the animal experiments noted below for NR2F6 will be leveraged for Entest. Excellent addition to the Regen team with Dr Ma. Of all the programs going on at Regen, NR2F6 is the program that could yield a therapy for Entest.
Waiting for Regen to explode one of these days. Yes in that one too.
GLTA.
Regen BioPharma, Inc. Announces the Appointment of Xiaojing Ma, PhD as the Company's New Senior Research Advisor
Font size: A | A | A
8:00 AM ET 9/29/16 | PR Newswire
Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) is pleased to announce that Xiaojing Ma, Ph.D. has agreed to serve in the consulting role as the Company's Senior Research Advisor. Specifically, he will be assisting Dr. Lander in pre-clinical research design and execution of cellular and animal experiments for the Company's NR2F6 program.
Dr. Ma has been studying cytokines, particularly the IL-10 and IL-12 family of interleukins, for more than 20 years in many aspects of their regulation and immunobiology in various inflammatory autoimmune and tumor-immune models. Dr. Ma's group first identified a novel function of the Crohn's disease-associated NOD2 mutation and uncovered the mechanisms by which IL-12 induces strong cell-mediated immune responses against various malignancies. He was also the first to identify a novel, non-chemokine activity of CCL5 in the generation and function of myeloid-derived suppressor cells and tumor-associated macrophages in the regulation of immune responses against breast cancer/mammary tumor.
"I am pleased to have Dr. Ma assist us in our cellular and animal studies as we move the NR2F6 small molecule program forward. He is an expert in understanding how the human immune system functions in response to various stimuli, and his participation in the program will accelerate the development of small molecule drugs," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.
AI
